BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37768408)

  • 1. Caffeine reduces viability, induces apoptosis, inhibits migration and modulates the CD39/CD73 axis in metastatic cutaneous melanoma cells.
    Manica D; da Silva GB; de Lima J; Cassol J; Dallagnol P; Narzetti RA; Moreno M; Bagatini MD
    Purinergic Signal; 2023 Sep; ():. PubMed ID: 37768408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells.
    da Silva GB; Manica D; da Silva AP; Marafon F; Moreno M; Bagatini MD
    Chem Biol Interact; 2023 Apr; 375():110427. PubMed ID: 36863647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin modulates purinergic signaling and inflammatory response in cutaneous metastatic melanoma cells.
    Manica D; da Silva GB; Narzetti RA; Dallagnoll P; da Silva AP; Marafon F; Cassol J; de Souza Matias L; Zamoner A; de Oliveira Maciel SFV; Moreno M; Bagatini MD
    Purinergic Signal; 2024 May; ():. PubMed ID: 38801619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin promotes apoptosis of human melanoma cells by caspase 3.
    Manica D; Silva GBD; Silva APD; Marafon F; Maciel SFVO; Bagatini MD; Moreno M
    Cell Biochem Funct; 2023 Dec; 41(8):1295-1304. PubMed ID: 37792322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1α, 25-Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells.
    Bagatini MD; Bertolin K; Bridi A; Pelinson LP; da Silva Rosa Bonadiman B; Pillat MM; Gonçalves PBD; Ulrich H; Schetinger MRC; Morsch VM
    J Cell Biochem; 2019 Jun; 120(6):9992-10000. PubMed ID: 30548323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istradefylline modulates purinergic enzymes and reduces malignancy-associated factors in B16F10 melanoma cells.
    da Silva JLG; Viana AR; Passos DF; Krause LMF; Miron VV; Schetinger MRC; Pillat MM; Palma TV; Leal DBR
    Purinergic Signal; 2023 Dec; 19(4):633-650. PubMed ID: 36522571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crowding within synaptic junctions influences the degradation of nucleotides by CD39 and CD73 ectonucleotidases.
    Rahmaninejad H; Pace T; Chun BJ; Kekenes-Huskey PM
    Biophys J; 2022 Jan; 121(2):309-318. PubMed ID: 34922916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
    Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD39 abrogates platelet-derived factors induced IL-1β expression in the human placenta.
    Forstner D; Guettler J; Brugger BA; Lyssy F; Neuper L; Daxboeck C; Cvirn G; Fuchs J; Kraeker K; Frolova A; Valdes DS; Stern C; Hirschmugl B; Fluhr H; Wadsack C; Huppertz B; Nonn O; Herse F; Gauster M
    Front Cell Dev Biol; 2023; 11():1183793. PubMed ID: 37325567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.
    Muñóz-Godínez R; de Lourdes Mora-García M; Weiss-Steider B; Montesinos-Montesinos JJ; Del Carmen Aguilar-Lemarroy A; García-Rocha R; Hernández-Montes J; Azucena Don-López C; Ávila-Ibarra LR; Torres-Pineda DB; Molina-Castillo G; Chacón-Salinas R; Vallejo-Castillo L; Pérez-Tapia SM; Monroy-García A
    Mediators Inflamm; 2020; 2020():1678780. PubMed ID: 33488292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism.
    Spatola BN; Lerner AG; Wong C; Dela Cruz T; Welch M; Fung W; Kovalenko M; Losenkova K; Yegutkin GG; Beers C; Corbin J; Soros VB
    MAbs; 2020; 12(1):1838036. PubMed ID: 33146056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.
    da Silva GB; Manica D; da Silva AP; Kosvoski GC; Hanauer M; Assmann CE; Simões JLB; Pillat MM; de Lara JD; Marafon F; Bertollo AG; Mingoti MED; Gavioli J; Réus GZ; de Oliveira GG; Ignácio ZM; Bagatini MD
    J Mol Med (Berl); 2022 Apr; 100(4):645-663. PubMed ID: 35249135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
    Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
    Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction.
    Knight JS; Mazza LF; Yalavarthi S; Sule G; Ali RA; Hodgin JB; Kanthi Y; Pinsky DJ
    Front Immunol; 2018; 9():1322. PubMed ID: 29942314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
    Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R
    Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer.
    Gardani CFF; Pedrazza EL; Paz VS; Zanirati GG; da Costa JC; Andrejew R; Ulrich H; Scholl JN; Figueiró F; Rockenbach L; Morrone FB
    Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
    Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
    Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.